Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let’s stay connected!
To submit a correction request, please visit our Contact Us page.
GlobalData tracks 15 drugs in development for Herpes Labialis (Oral Herpes) by 11 companies/universities/institutes. The top development phase for Herpes Labialis (Oral Herpes) is preclinical,
The FDA handed down a complete response letter to Aldeyra Therapeutics for its dry eye disease drug reproxalap, following months of speculation about whether the
The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease
STAT Virtual Event | How to Increase Diversity in Clinical Trials: Strategies & Tools
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let’s stay connected!
To submit a correction request, please visit our Contact Us page.
Herpes Labialis (Oral Herpes) drugs in development, 2023
GlobalData tracks 15 drugs in development for Herpes Labialis (Oral Herpes) by 11 companies/universities/institutes. The top development phase for Herpes Labialis (Oral Herpes) is preclinical,
Aldeyra’s dry eye drug gets a rejection from the FDA
The FDA handed down a complete response letter to Aldeyra Therapeutics for its dry eye disease drug reproxalap, following months of speculation about whether the
FDA approves Lilly ulcerative colitis treatment with a new approach to tamping down inflammation
The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease